Mazor Robotics Gets a Hold Rating from Needham

By Jason Carr

In a report released today, Michael Matson from Needham reiterated a Hold rating on Mazor Robotics (NASDAQ: MZOR). The company’s shares opened today at $44.25, close to its 52-week high of $47.28.

Matson said:

“MZOR is entering the second phase of its partnership with MDT which consists of an additional equity investment by MDT of $40M and MDT assuming global distribution of the Mazor X. We think the agreement is positive for MZOR and MDT and negative for NUVA.”

According to TipRanks.com, Matson is a 5-star analyst with an average return of 12.0% and a 61.5% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.

Mazor Robotics has an analyst consensus of Moderate Buy, with a price target consensus of $54.

The company has a one year high of $47.28 and a one year low of $20.19. Currently, Mazor Robotics has an average volume of 380.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mazor Robotics Ltd. is a medical device company, which engages in the development and marketing of innovative surgical guidance systems and complementary products. It specializes in robotic, computerized and imaging-based systems, primarily in the field of spine surgery.